Goodwin: Fusion Pharmaceuticals to Be Acquired By AstraZeneca
March 21, 2024
March 21, 2024
BOSTON, Massachusetts, March 21 -- Goodwin, a law firm, issued the following news release:
The M&A team advised Fusion Pharmaceuticals (Nasdaq: FUSN) in its definitive agreement to be acquired by AstraZeneca.
Under the terms of the agreement AstraZeneca, through a subsidiary, will acquire all of Fusion's outstanding shares pursuant to a plan of arrangement for a price of $21.00 per share in cash at closing plus a non-transferable contingent value right (CVR) of . . .
The M&A team advised Fusion Pharmaceuticals (Nasdaq: FUSN) in its definitive agreement to be acquired by AstraZeneca.
Under the terms of the agreement AstraZeneca, through a subsidiary, will acquire all of Fusion's outstanding shares pursuant to a plan of arrangement for a price of $21.00 per share in cash at closing plus a non-transferable contingent value right (CVR) of . . .